Testing radiation plus a mix of drugs for breast cancer that has spread to the brain
Official title: Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests radiation given along with several drugs for a type of breast cancer that has spread to the brain.
Read our full plain-language summary
What the trial team says
This is an open-label, prospective, two-arm, multicenter phase II clinical trial. The aim is to explore the efficacy and safety of radiotherapy combined with cisplatin/carboplatin, adebrelimab, and bevacizumab in patients with triple-negative breast cancer and brain metastases.
Key facts
- Registry number
- NCT07638852
- Stage of testing
- Phase 2
- Conditions studied
- TNBC, Triple Negative Breast Cancer, Brain Metastasases
Where it is running
This trial lists 1 site.
-
Shanghai Municipality
- Fudan University Shanghai Cancer Center (Shanghai)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.